Bridging the gap between the clinician and the patient with cryopyrin-associated periodic syndromes

International Journal of Immunopathology and Pharmacology

Volumn 24, Issue 4, 2011, Pages 827-836

  Cantarini, Luca ^a   Lucherini, O M ^a   Frediani, B ^a   Brizi, M G ^a   Bartolomei, B ^b   Cimaz, R ^c   Galeazzi, M ^a   Rigante, D ^b  

^a UNIVERSITY OF SIENA   (Italy)

^b FONDAZIONE POLICLINICO UNIVERSITARIO A GEMELLI IRCCS   (Italy)

^c UNIVERSITY OF FLORENCE   (Italy)

Author keywords

Chronic infantile neurological cutaneous articular syndrome; Cryopyrin associated periodic syndromes; Familial cold autoinflammatory syndrome; Muckle Wells syndrome; Neonatal onset multisystem inflammatory disease

Indexed keywords

AMYLOID A PROTEIN; C REACTIVE PROTEIN; CANAKINUMAB; CORTICOSTEROID; RECOMBINANT INTERLEUKIN 1 RECEPTOR BLOCKING AGENT; RILONACEPT; ANTIHISTAMINIC AGENT; ANTIINFLAMMATORY AGENT; DISEASE MODIFYING ANTIRHEUMATIC DRUG; IMMUNOSUPPRESSIVE AGENT; INTERLEUKIN 1; THALIDOMIDE; TUMOR NECROSIS FACTOR INHIBITOR;

CINCA SYNDROME; CYTOKINE PRODUCTION; DOCTOR PATIENT RELATION; DRUG MEGADOSE; EARLY DIAGNOSIS; ERYTHROCYTE SEDIMENTATION RATE; FAMILIAL COLD AUTOINFLAMMATORY SYNDROME; GASTROENTERITIS; GENE MUTATION; GENE SEQUENCE; HUMAN; IMMUNE RESPONSE; INFLAMMATION; INJECTION SITE PAIN; INJECTION SITE REACTION; LOADING DRUG DOSE; MUCKLE WELLS SYNDROME; NUCLEAR MAGNETIC RESONANCE IMAGING; PRIORITY JOURNAL; RADIOGRAPHY; REMISSION; REVIEW; RHINOPHARYNGITIS; TREATMENT RESPONSE; UPPER RESPIRATORY TRACT INFECTION; VERTIGO; CENTRAL NERVOUS SYSTEM; JOINT; SKIN;

EID: 84856571891     PISSN: 03946320     EISSN: None     Source Type: Journal    
DOI: 10.1177/039463201102400402     Document Type: Review

References (40)

1. Rigante D. The protean visage of systemic autoinflammatory syndromes. Eur Rev Med Pharmacol Sci 2010; 14:1-18.
2. Neven B, Prieur AM, Quartier Dit Maire P. Cryopyrinopathies: update on pathogenesis and treatment. Nat Clin Pract Rheumatol 2008; 4:481-89.
3. Ye Z, Ting JP. NLR, the nucleotide-binding domain leucine-rich repeat containing gene family. Curr Opin Immunol 2008; 20:3-9.
4. Agostini L, Martinon F, Burns K, Mcdermott MF, Hawkins PN, Tschopp J. NALP3 forms an IL-1beta-processing inflammasome with increased activity in Muckle-Wells autoinflammatory disorder. Immunity 2004; 20:319-25. (Pubitemid 38388233)
5. Hoffman HM, Mueller JL, Broide DH, Wanderer AA, Kolodner RD. Mutation of a new gene encoding a putative pyrin-like protein causes familial cold autoinflammatory syndrome and Muckle-Wells syndrome. Nat Genet 2001; 29:301-5. (Pubitemid 33096455)
6. Shinkai K, McCalmont TH, Leslie KS. Cryopyrin-associated periodic syndrome and autoinflammation. Clin Exp Dermatol 2008; 33:1-9.
7. Hoffman HM, Wanderer AA, Broide DH. Familial cold autoinflammatory syndrome: phenotype and genotype of an autosomal dominant periodic fever. J Allergy Clin Immunol 2001; 108:615-20. (Pubitemid 32978035)
8. Doeglas HM, Bleumink E. Familial cold urticaria. Clinical findings. Arch Dermatol 1974; 110:382-88.
9. Muckle TJ, Wells M. Urticaria, deafness, and amyloidosis: a new heredo-familial syndrome. Q J Med 1962; 31:235-48.
10. Lequerre T, Vittecoq O, Saugier-Veber P, et al. A cryopyrin-associated periodic syndrome with joint destruction. Rheumatology (Oxford) 2007; 46:709-14. (Pubitemid 46523322)
11. Lorber J. Syndrome for diagnosis: dwarfing, persistently open fontanelle; recurrent meningitis; recurrent subdural effusions with temporary alternate-sided hemiplegia; high-tone deafness; visual defect with pseudopapilloedema; slowing intellectual development; recurrent acute polyarthritis; erythema marginatum, splenomegaly and iron-resistant hypochromic anaemia. Proc R Soc Med 1973; 66:1070-71.
12. Prieur AM. A recently recognised chronic inflammatory disease of early onset characterised by the triad of rash, central nervous system involvement and arthropathy. Clin Exp Rheumatol 2001; 19:103-6.
13. Hill SC, Namde M, Dwyer A, Poznanski A, Canna S, Goldbach-Mansky R. Arthropathy of neonatal onset multisystem inflammatory disease (NOMID/ CINCA). Pediatr Radiol 2007; 37:145-52.
14. Kitley JL, Lachmann HJ, Pinto A, Ginsberg L. Neurologic manifestations of the cryopyrin-associated periodic syndrome. Neurology 2010; 74:1267-70.
15. Aksentijevich I, Nowak M, Mallah M, et al. De novo CIAS1 mutations, cytokine activation, and evidence for genetic heterogeneity in patients with neonatal-onset multi system inflammatory disease (NOMID): a new member of the expanding family of pyrin-associated autoinflammatory diseases. Arthritis Rheum 2002; 46:3340-48. (Pubitemid 35453546)
16. Arend WP, Palmer G, Gabay C. IL-1, IL-18, and IL-33 families of cytokines. Immunol Rev 2008; 223:20-38. (Pubitemid 351986169)
17. Martinon F, Burns K, Tschopp J. The inflammasome: a molecular platform triggering activation of inflammatory caspases and processing of proIL-beta. Mol Cell 2002; 102:417-26. (Pubitemid 35007355)
18. Jesus AA, Silva CA, Segundo GR, et al. Phenotype-genotype analysis of cryopyrin-associated periodic syndromes (CAPS): description of a rare non-exon 3 and a novel CIASl missense mutation. J Clin Immunol 2008; 28:134-38. (Pubitemid 351328954)
19. Frenkel J, van Kempen MJ, Kuis W, van Amstel HK. Variant chronic infantile neurologic, cutaneous, articular syndrome due to a mutation within the leucine-reach repeat domain of CIAS1. Arthritis Rheum 2004; 50:2719-20. (Pubitemid 39062743)
20. Aganna E, Martinon F, Hawkins PN, et al. Association of mutations in the NALP3/CIAS1/PYPAF1 gene with a broad phenotype including recurrent fever, cold sensitivity, sensorineural deafness, and AA amyloidosis. Arthritis Rheum 2002; 46:2445-52.
21. Aksentijevich I, D Putnam C, Remmers EF, et al. The clinical continuum of cryopyrinopathies: novel CIAS1 mutations in North American patients and a new cryopyrin model. Arthritis Rheum 2007; 56:1273-85.
22. Cuisset L, Jeru I, Dumont B, et al. Mutations in the autoinflammatory cryopyrin-associated periodic syndrome gene: epidemiological study and lessons from eight year of genetic analysis in France. Ann Rheum Dis 2011; 70:495-9.
23. Stojanov S, Kastner DL. Familial autoinflammatory diseases: genetics, pathogenesis and treatment. Curr Opin Rheumatol 2005; 17:586-99. (Pubitemid 41527820)
24. Pietzsch J, Hoppmann S. Human S100A12: a novel key player in inflammation? Amino Acids 2009; 36:381-89.
25. Aït-Abdesselam T, Lequerré T, Legallicier B, François A, Le Loët X, Vittecoq O. Anakinra efficacy in a Caucasian patient with renal AA amyloidosis secondary to cryopyrin-associated periodic syndrome. Joint Bone Spine 2010; 77:616-17.
26. Haas N, Küster W, Zuberbier T, Henz BM. Muckle-Wells syndrome: clinical and histological skin findings compatible with cold air urticaria in a large kindred. Br J Dermatol 2004; 151:99-104. (Pubitemid 39061285)
27. Hoffman HM, Wolfe F, Belomestnov P, Mellis SJ. Cryopyrin-associated periodic syndromes: development of a patient-reported outcomes instrument to assess the pattern and severity of clinical disease activity. Curr Med Res Opin 2008; 24:2531-43.
28. Ross JB, Finlayson LA, Klotz PJ, et al. Use of anakinra (Kineret) in the treatment of familial cold autoinflammatory syndrome with a 16-month follow-up. J Cutan Med Surg 2008; 12:8-16. (Pubitemid 351363467)
29. O'Connell SM, O'Regan GM, Bolger T, et al. Response to IL-1-receptor antagonist in a child with familial cold autoinflammatory syndrome. Pediatr Dermatol 2007; 24:85-9.
30. Hoffman HM, Rosengren S, Boyle DL, et al. Prevention of cold-associated acute inflammation in familial cold autoinflammatory syndrome by interleukin-1 receptor antagonist. Lancet 2004; 364:1779-85. (Pubitemid 39488063)
31. Hawkins PN, Lachmann HJ, Aganna E, McDermott MF. Spectrum of clinical features in Muckle-Wells syndrome and response to anakinra. Arthritis Rheum 2004; 50:607-12. (Pubitemid 38198844)
32. Mirault T, Launay D, Cuisset L, et al. Recovery from deafness in a patient with Muckle-Wells syndrome treated with anakinra. Arthritis Rheum 2006; 54:1697-700.
33. Goldbach-Mansky R, Dailey NJ, Canna SW, et al. Neonatal-onset multisystem inflammatory disease responsive to interleukin-1 beta inhibition. N Engl J Med 2006; 355:581-92. (Pubitemid 44200651)
34. Lepore L, Paloni G, Caorsi R, et al. Follow-up and quality of life of patients with cryopyrin-associated periodic syndromes treated with Anakinra. J Pediatr 2010; 157:310-15.
35. Yu JR, Leslie KS. Cryopyrin-associated periodic syndrome: an update on diagnosis and treatment response. Curr Allergy Asthma Rep 2011; 11:12-20.
36. Rigante D, Stabile A, Minnella A, et al. Postinflammatory retinal dystrophy in CINCA syndrome. Rheumatol Int 2010; 30:389-93.
37. Goldbach-Mansky R, Shroff SD, Wilson M, et al. A pilot study to evaluate the safety and efficacy of the long-acting interleukin-1 inhibitor rilonacept (interleukin-1 Trap) in patients with familial cold autoinflammatory syndrome. Arthritis Rheum 2008; 58:2432-42.
38. Hoffman HM. Rilonacept for the treatment of cryopyrin-associated periodic syndromes (CAPS). Expert Opin Biol Ther 2009; 9:519-31.
39. Savic S, McDermottMF. Inflammation: canakinumab for the cryopyrin-associated periodic syndromes. Nat Rev Rheumatol 2009; 5:529-30.
40. Lachmann HJ, Kone-Paut I, Kuemmerle-Deschner JB, et al. Use of canakinumab in the cryopyrin-associated periodic syndrome. N Engl J Med 2009; 360:2416-25.